Genmab A/S develops antibody medicines for cancer and other serious diseases through therapeutic formats that include bispecific antibodies, antibody-drug conjugates, immune-modulating antibodies and other next-generation modalities. Company news commonly centers on clinical data, regulatory interactions and portfolio decisions for programs such as EPKINLY®/epcoritamab, rinatabart sesutecan (Rina-S®) and petosemtamab.
Recurring updates also cover collaborations and commercialization economics tied to antibody products, including DARZALEX® royalties under the Johnson & Johnson license, EPKINLY development with AbbVie, research partnerships, and capital or shareholder announcements. Genmab’s disclosures frequently connect pipeline progress with hematologic malignancies, solid tumors and the company’s broader antibody-technology strategy.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.